{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:18:55Z","timestamp":1794651535110,"version":"4.9.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Distinguishing between poorly differentiated urothelial carcinoma and high-grade prostatic adenocarcinoma is a common challenge in genitourinary pathology, particularly when the tumor involves the bladder neck or prostatic urethra. Clinically, the distinction between these 2 tumors can also be difficult. Proper diagnosis in these patients is essential as they have differing prognoses and clinical management. GATA3 is thought to be a sensitive and relatively specific marker of urothelial carcinoma. However, there is scant data regarding GATA3 labeling of high-grade prostatic adenocarcinoma. The aim of this study is to describe rare cases with strong aberrant GATA3 staining in prostatic adenocarcinoma as a potential diagnostic pitfall. We identified 9 cases of prostatic adenocarcinoma with aberrant positive GATA3 staining from 2015 to 2020 as part of a large consultation service at our institution. All 9 cases were grade group 5, 8 had a Gleason score of 5+5=10 and 1 had a score of 4+5=9. Five of the cases were from the prostate, 3 from the urinary bladder, and 1 from the prostatic urethra. All cases were morphologically typical of high-grade prostatic adenocarcinoma, although were sent for consultation due to uncertainty in the diagnosis. GATA3 positivity was strong, diffuse in 4 cases; strong, patchy in 2 cases and strong, focal in 3 cases. All cases were positive for NKX3.1, 6 positive for p501s, and 6 positive for PSA, with 7\/9 cases showing expression of at least 2 prostate-specific markers. The current study describes that rare cases of prostatic adenocarcinoma can show focal or diffuse strong staining for GATA3. In order to avoid this diagnostic pitfall, undifferentiated carcinomas involving the prostate, bladder neck, or trigone should be evaluated not only with GATA3 but also prostate-specific markers.<\/jats:p>","DOI":"10.1097\/pas.0000000000001557","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T07:48:18Z","timestamp":1596872898000},"page":"341-346","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Aberrant GATA3 Staining in Prostatic Adenocarcinoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Timothy M.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/modpathol.2013.76","article-title":"GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma","volume":"26","author":"So","year":"2013","journal-title":"Mod Pathol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.humpath.2017.05.009","article-title":"T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation","volume":"65","author":"Dorfman","year":"2017","journal-title":"Hum Pathol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors","volume":"38","author":"Miettinen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/PAP.0b013e3182a28a68","article-title":"Value of GATA3 immunostaining in tumor diagnosis: a review","volume":"20","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0b013e3181908e24","article-title":"Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations","volume":"33","author":"Esheba","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/01.pas.0000213438.01278.5f","article-title":"Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray","volume":"31","author":"Higgins","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1309\/AJCP5UAFMSA9ZQBZ","article-title":"Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas","volume":"138","author":"Liu","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/PAS.0b013e318260cde7","article-title":"Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung","volume":"36","author":"Chang","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PAS.0000000000000798","article-title":"GATA3 positivity in benign radiated prostate glands: a potential diagnostic pitfall","volume":"41","author":"Wobker","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1309\/PYQC-17CB-063T-Q07J","article-title":"Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas","volume":"113","author":"Kaufmann","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"R11-20250608","first-page":"5501","article-title":"Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder","volume":"9","author":"Koga","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/his.12360","article-title":"Uroplakin II outperforms uroplakin III in diagnostically challenging settings","volume":"65","author":"Smith","year":"2014","journal-title":"Histopathology"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.urology.2007.11.128","article-title":"Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer","volume":"72","author":"Matsumoto","year":"2008","journal-title":"Urology"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200301000-00001","article-title":"Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas","volume":"27","author":"Parker","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.humpath.2014.09.007","article-title":"Utility of uroplakin II expression as a marker of urothelial carcinoma","volume":"46","author":"Tian","year":"2015","journal-title":"Hum Pathol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/PAS.0b013e31802f5d33","article-title":"Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma","volume":"31","author":"Chuang","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ajcp\/110.3.385","article-title":"Thrombomodulin expression in transitional cell carcinoma","volume":"110","author":"Ord\u00f3\u00f1ez","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2559.2003.01560.x","article-title":"High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer","volume":"42","author":"Varma","year":"2003","journal-title":"Histopathology"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/modpathol.2014.115","article-title":"Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas","volume":"28","author":"Tan","year":"2015","journal-title":"Mod Pathol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/00000478-200209000-00005","article-title":"Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody","volume":"26","author":"Oliai","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"Gurel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/PAS.0000000000000238","article-title":"Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0094-0143(21)00928-9","article-title":"PSA and PAP as immunohistochemical markers in prostate cancer","volume":"20","author":"Epstein","year":"1993","journal-title":"Urol Clin North Am"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1309\/V1RY91NKX5ARW2Q5","article-title":"Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and\/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma","volume":"125","author":"Kunju","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1053\/hupa.2002.129416","article-title":"Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma","volume":"33","author":"Mhawech","year":"2002","journal-title":"Hum Pathol"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pros.20043","article-title":"Prostein expression is highly restricted to normal and malignant prostate tissues","volume":"60","author":"Kalos","year":"2004","journal-title":"Prostate"},{"key":"R27-20250608","first-page":"1563","article-title":"Identification and characterization of prostein, a novel prostate-specific protein","volume":"61","author":"Xu","year":"2001","journal-title":"Cancer Res"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/PAS.0b013e3180536678","article-title":"The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate","volume":"31","author":"Sheridan","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/PAS.0000000000000178","article-title":"Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall","volume":"38","author":"Gordetsky","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/PAS.0000000000001112","article-title":"Prostatic adenocarcinoma with focal pleomorphic giant cell features: a series of 30 cases","volume":"42","author":"Alharbi","year":"2018","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:05:11Z","timestamp":1749420311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001557"}},"subtitle":["A Potential Diagnostic Pitfall"],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001557","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,4]]}}}